Strain of genus Bortera expressing serum type 3 fimbriae
By developing the BPZE1f3 vaccine, the strains of pertussis bautista genus of serum type 2 and serum type 3 pili have been solved, and the shortcomings of existing vaccines in reducing the colonization and transmission protection of asymptomatic bautista are achieved. The significant protection and stable immune response of the genus.
Patent Information
- Application Number
- CN202411102248.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-10-18
- Filing Date
- 2018-10-18
- Publication Date
- 2024-11-19
AI Technical Summary
The existing pertussis vaccine is not effective in reducing asymptomatic bauterus colonization and cannot effectively protect the spread of pertussis, especially in young infants who have not received primary vaccination series protection.
The BPZE1f3 vaccine was developed, derived from the pertussis strain that produces serum type 2 and serum type 3 pili, which forms a stable subtraction by adding a single C:G base pair to the fim3 promoter region to allow fim3 expression. The virulent Bauteri strain retains the ability to colonize and induce a protective immune response in the lungs of mammalian subjects.
The BPZE1f3 vaccine significantly improved the protective effect on clinical isolates that produce only Fim3, and demonstrated a long-term protective immune response and stable Fim3 expression in mouse models, reducing nasopharyngeal infection of Bautista pertussis, providing more Strong serum specific protection.
Smart Images

Figure BDA0004989686900000151 
Figure HDA0004989686910000011 
Figure HDA0004989686910000021
Abstract
Description
[0001] This application is a divisional application of an application filed on October 18, 2018, with application number 201880067004.8 and invention name “Bordeia strain expressing serotype 3 fimbriae”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 574,068, filed on October 18, 2017.
[0004] Sequence Listing
[0005] This application contains a sequence listing that has been submitted electronically in ASCII format, and the sequence listing is hereby incorporated by reference in its entirety. The ASCII copy created on October 10, 2018 is named 7056-0091_SL and is 1,833 bytes in size. Technical Field
[0006] The present invention relates generally to the fields of microbiology, immunology, vaccinology, sero-epidemiology, biochemistry and medicine. More specifically, the present invention relates to live attenuated Bordetella strains modified to express serotype 3 pili and their use in vaccines. Background Art
[0007] Whooping cough, or pertussis, is a serious respiratory disease that can be life-threatening, especially in young infants, and its incidence is still rising in some countries despite a global vaccination coverage of more than 85%, according to the World Health Organization. However, it also infects adolescents and adults, and symptoms in adolescents and adults are often atypical, so the disease is often undiagnosed in these age groups. But even if adolescents and adults remain asymptomatic, they can spread the causative agent, Bordetella pertussis, to young infants who have not received the protection of the primary vaccination series. In fact, recent wavelet analysis of Bordetella pertussis infection in the United States and the United Kingdom combined with photodynamic analysis of clinical isolates showed that asymptomatic transmission is the main cause of recent recurrences of pertussis disease. In addition, asymptomatic Bordetella pertussis infection may not be insignificant, as epidemiological evidence suggests that Bordetella pertussis infection may be associated with autoimmune diseases (e.g., celiac disease, multiple sclerosis, and even Alzheimer's disease).
[0008] Currently available whole-cell or acellular vaccines are highly effective in reducing the incidence of pertussis after three primary vaccination doses. However, they are less effective in reducing asymptomatic colonization, as opposed to prior infection with B. pertussis, as recently shown in a baboon model. Although vaccinated baboons were protected against pertussis disease following experimental infection with B. pertussis, they were easily infected and transmitted the organism to littermates, even in the absence of symptoms. Altogether, these observations illustrate the shortcomings of currently available vaccines and the need for new vaccines that protect against both disease and infection.
[0009] Based on the observation that the best protection against colonization with Bordetella pertussis is infection first, a live attenuated vaccine that can be administered by the nasal route has been developed to mimic natural infection as closely as possible without causing disease. The vaccine strain, called BPZE1, lacks the gene encoding the dermonecrotic toxin, produces genetically detoxified pertussis toxin, and lacks tracheal cytotoxin production by replacing the Bordetella pertussis ampG gene with the Escherichia coli ampG gene. BPZE1 has been shown to be safe in preclinical models, including in severely immunocompromised mice, and is genetically stable after serial passage in vitro and in vivo for at least 12 months. After a single nasal administration, it protects mice from Bordetella pertussis challenge by both protective CD4+ T cells and antibodies, and this protection has been shown to be long-term after a single nasal vaccination. It has also recently been shown to reduce Bordetella pertussis nasopharyngeal infection in baboons by 99.992% compared to unvaccinated baboons. The first-in-human Phase I clinical trial of BPZE1 has now been successfully completed and found that BPZE1 is safe in adults, can transiently colonize the human nasopharynx and can induce immune responses against all tested antigens in all colonized individuals.
[0010] Bordetella pertussis produces two serologically different pili, consisting of either Fim2 or Fim3 as the major pili subunit. These pili are involved in the attachment of bacteria to respiratory epithelial cells. Although BPZE1 only produces Fim2, it also produces hundreds of other antigens (e.g., pertussis toxin, FHA, and pertactin). Therefore, it has been shown to induce significant protection against a wide variety of Bordetella pertussis clinical isolates (including those that only produce Fim3). Summary of the invention
[0011] Described herein is the development of BPZE1f3 (deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) (Institut Pasteur, 25 rue du Docteur Roux, Cedex, Paris 15, F-75724, France) on October 11, 2017 under the registration number CNCM I-5247), a Bordetella pertussis strain derived from BPZE1 that produces both serotype 2 fimbriae (Fim2) and serotype 3 fimbriae (Fim3). Given that BPZE1 produces hundreds of different non-fimbriae antigens that can be targeted by an immune response, it is not expected that the addition of a single neoantigen would have much impact on the protection of the bacteria. Surprisingly, vaccination with BPZE1f3 was found to significantly improve protection against certain clinical isolates that produce Fim3 but not Fim2.
[0012] In the studies described in the Examples section below, the intranasal mouse challenge model was used to examine the protective potential of BPZE1 producing Fim2 and BPZE1f3 producing Fim2 and Fim3 to protect against clinical isolates of different serotypes. Both vaccine strains appeared to induce significant protection against all clinical isolates examined. However, against clinical isolates producing only Fim3, BPZE1f3 provided significantly better protection than BPZE1, thus confirming to some extent serospecific protection.
[0013] A variety of Fim2 and Fim3 subtypes have been identified. These subtypes include two Fim2 subtypes (i.e., Fim2-1, Fim2-2) that differ from each other by only a single amino acid. Fim2-1 carries an arginine at position 174, while Fim2-2 carries a lysine at said position. Fim3 subtypes are encoded by 6 different alleles. Fim3-2 differs from Fim3-1 by a single amino acid substitution at position 87: alanine and glutamic acid, respectively, in Fim3-1 and Fim3-2. In addition to the glutamic acid substitution at position 87, Fim3-3 also carries a change from a threonine in Fim3-1 to an alanine in Fim3-3. The fim3-4 allele differs from fim3-1 by only a single silent nucleotide polymorphism, while the other five alleles differ by three different codons, each of which results in an amino acid change in the major pili subunit. Considering the minor sequence differences between the various subtypes, BPZE1f3 may play a protective role against all subtypes.
[0014] To induce an immune response to the fimbrial antigens, the production of these antigens must be sufficiently stable in live Bordetella pertussis vaccine strains. The stability of Fim2 and Fim3 production deserves special attention because phase changes from one serotype to another have been described (especially during infection) and can be driven by vaccine pressure. This phase change from high to low fimbrial production depends on the number of cytosines present in the C-strand (string) in the fim promoter region. The number of cytosines in this C-strand may affect the distance between the -10 region of the fim promoter and the BvgA binding site, which is a transcriptional activator required for the expression of fim and other Bordetella pertussis virulence genes. It has long been known that DNA regions with repeated base pair sequences (mainly in the C-strand) are particularly prone to the addition or deletion of single bases. Since BPZE1f3 is constructed by adding a single C:G base pair in the 13 C segment of the promoter region to allow fim3 expression, it is believed that fim3 expression is unstable. However, unexpectedly, after BPZE1f3 was passaged through mice several times, 100% of the bacteria recovered after the first passage were still Fim3+ and Fim2+. During subsequent passages (up to 3 times), nearly 90% of the bacteria still expressed both fim3 and fim2, indicating that fim expression is stable enough to induce serotype-specific immunity, as confirmed by the protective effect of BPZE1f3 against clinical isolates that only produce Fim3.
[0015] Thus, described herein are attenuated live Bordetella strains engineered to stably produce Fim3, wherein the attenuated live Bordetella strains retain the ability to colonize the lungs of a mammalian subject and induce a protective immune response to Bordetella infection (e.g., the Bordetella strain is designated as BPZE1f3). The attenuated live Bordetella strain can be a strain that also stably produces Fim2. The attenuated live Bordetella strains described herein can also be determined to lack at least one (1, 2, or 3) of the following virulence factors: functional pertussis toxin (PTX), functional dermonecrotic toxin (DNT), and functional tracheocytotoxin (TCT).
[0016] Also described herein is a vaccine comprising a live attenuated Bordetella strain engineered to stably produce Fim3 as described herein and a pharmaceutically acceptable carrier. The vaccine can be provided in a single dosage form comprising at least 1 x 10 6 (For example, at least 1 x 10 6 , 5 x 10 6 , or 1 x 10 7 ) colony forming units (CFU) of the strain.
[0017] Further described herein is a method of protecting a mammalian subject (e.g., a human) from pertussis, the method comprising the steps of administering to the mammalian subject a vaccine comprising a pharmaceutically acceptable carrier and a live attenuated Bordetella strain engineered to stably produce Fim3, wherein the live attenuated Bordetella strain retains the ability to colonize the lungs of the mammalian subject and to induce a protective immune response against Bordetella infection.
[0018] As used herein, a bacterial strain that "stably produces" an antigen is a bacterial strain that can be passaged through a host animal at least once (e.g., 1, 2, 3, 4, 5 or more times) without losing more than 50% (or more than 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99%) of the expression of the antigen. For example, an isolated Bordetella strain engineered to stably produce Fim3 is a strain that is genetically modified to express Fim3 and retains at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99%) of the expression of Fim-3 after passage through mice (e.g., by the methods described in the Examples section below).
[0019] Reference to a "functional" virulence factor means that the bacterial strain has at least 50% of the enzymatic activity of the virulence factor (compared to the wild-type form of the virulence factor). A bacterial strain "determined to lack at least one virulence factor" is a strain that has been engineered to express less than 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the enzymatic or functional activity of the virulence factor compared to the parent strain from which it was derived.
[0020] Unless otherwise defined, all technical terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patents and patent applications mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification including definitions shall prevail. In addition, the specific embodiments discussed below are for illustration only and are not intended to be limiting. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 A is a graph showing the production of Fim2 by BPZE1 (represented by diamonds) and BPZE1f3 (represented by squares).
[0022] Figure 1 B is a graph showing the production of Fim3 by BPZE1 (represented by diamonds) and BPZE1f3 (represented by squares).
[0023] Figure 2 A is a graph showing the in vitro growth of BPZE1 (represented by diamonds) and BPZE1f3 (represented by squares) in modified Stainer-Scholte medium.
[0024] Figure 2 B is a graph showing the in vitro growth of BPZE1 (represented by diamonds) and BPZE1f3 (represented by squares) in complete synthetic Thijs medium.
[0025] Figure 3 The nasal inoculation is shown in 10 6 Figure 3 is a graph of lung colonization of mice infected with 10 CFU of BPZE1 (in black) or BPZE1f3 (in grey), where bacterial loads in the lungs were measured at the indicated time points.
[0026] Figure 4 is a series of graphs (4A-4E) showing BPZE1-induced and BPZE1f3-induced protection against clinical Bordetella pertussis isolates in mice given intranasally for 10 5 CFU of BPZE1 (black bars) or BPZE1f3 (grey bars), or no treatment (white bars). 6 Mice were challenged with 1617pF1 (A), 403pF1 (B), P134 (C), 1412pF1 (D) or 403pF3 (E) with 10 CFU. Bacterial load in the lungs was measured 3 hours (left part of the inset, D0) or 7 days (right part of the inset, D7) after challenge and presented as mean and standard deviation of CFU. Three (for D0) or five (for D7) mice were used per group. ***, p<0.001.
[0027] Figure 5 is a graph comparing BPZE1-induced and BPZE1f3-induced protection against B. parapertussis in mice given intranasally for 10 6 Two months after vaccination, 10 6 Mice were challenged with 100 CFU of B. parapertussis. The bacterial load in the lungs was measured 3 hours (left part of the inset, D0) or 7 days (right part of the inset, D7) after challenge and presented as the mean and standard deviation of CFU. Three (for D0) or five (for D7) mice were used per group. ***, p<0.001.
[0028] Figure 6is a graph showing the stability of Fim2 and Fim3 production by BPZE1f3, where BPZE1f3 was passaged three times in mice and at each passage (P1 to P3), 94 colonies were analyzed by whole cell ELISA for the presence of Fim2 (white bars) and Fim3 (black bars) using anti-Fim2 and anti-Fim3 monoclonal antibodies. DETAILED DESCRIPTION
[0029] Described herein are BPZE1 derivatives that produce Fim3, which have sufficiently stable fim3 expression to provide improved protection in mice against clinical Bordetella pertussis isolates that produce only Fim3. The fim3 expression in BPZE1f3 does not change the protective efficacy against Fim2+ strains, nor does it change the protective efficacy against strains that produce neither Fim2 nor Fim3. The embodiments described below illustrate representative examples of these methods. Nevertheless, from the description of these embodiments, other aspects of the invention can be completed and / or practiced based on the description provided below.
[0030] General approach
[0031] Methods related to conventional microbiology, immunology, molecular biology, and medical technology are described herein. Microbiological methods are described in Methods for General and Molecular Microbiology (3rd edition), edited by Reddy et al., ASM Press. Immunological methods are generally known in the art and are described in methodological monographs, such as Current Protocols in Immunology, edited by Coligan et al., John Wiley & Sons, New York. The techniques of molecular biology are described in detail in the following monographs, e.g., Molecular Cloning: A Laboratory Manual, 2nd ed., Vols. 1-3, Sambrook et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001; and Current Protocols in Molecular Biology, Ausubel et al., eds., Greene Publishing and Wiley-Interscience, New York. The general approach to medical treatment is described in McPhee and Papadakis, Current Medical Diagnosis and Treatment 2010, 49th ed., McGraw-Hill Medical, 2010; and Fauci et al., Harrison's Principles of Internal Medicine, 17th ed., McGraw-Hill Professional, 2008.
[0032] Bordetella strains producing Fim3
[0033] Bordetella species lacking Fim3 expression (e.g., Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica) can be engineered to produce Fim3 (e.g., Fim3-1, Fim3-2, Fim3-3, or Fim3-4) and otherwise attenuated as described below. These Fim3-producing bacteria can be used to treat and / or prevent symptomatic or asymptomatic respiratory infections caused by Bordetella species and other conditions for which BPZE1 is shown to be effective (e.g., allergies and asthma). Bordetella strains engineered to produce Fim3 can also be used to prevent the spread of Bordetella infections. Attenuated, Fim2 / Fim3-producing Bordetella pertussis are preferably used in human subjects. Bordetella strains for use in preparing bacteria that produce Fim3 can be isolated from natural sources (e.g., colonized subjects) or obtained from various culture collections. Bordetella strains engineered to produce Fim3 can be prepared by the methods described below.
[0034] Because insufficient attenuation of pathogenic strains of Bordetella may cause pathological infection in a subject, it is preferred that the Bordetella strain engineered to produce Fim3 has lower levels of other virulence factors. On the other hand, in order to ensure that the Bordetella strain producing Fim3 can colonize a subject and exert a protective effect on respiratory inflammation, it cannot be overly attenuated. Attenuation can be achieved by mutating the strain to reduce its production of one or more (e.g., 1, 2, 3, 4, 5 or more) of the following: pertussis toxin (PTX), dermonecrotic toxin (DNT), tracheal cytotoxin (TCT), adenylate cyclase (AC), lipopolysaccharide (LPS), filamentous hemagglutinin (FHA), pertactin or any bvg regulatory component. Methods for preparing such mutants are described herein and in U.S. Patent No. 9,119,804 and U.S. Patent Application Serial No. 15 / 472,436. In the experiments presented below, a Bordetella strain was engineered to produce Fim3 that lacks DNT and TCT and produces genetically inactive PTX. It is able to colonize the respiratory tract of a subject and induce a protective immune response in the subject.
[0035] Formulation / Dosage / Administration
[0036] Bordetella strains engineered to produce Fim 3 can be formulated into a vaccine for administration to a subject. A suitable number of live bacteria are mixed with a pharmaceutically suitable excipient or carrier (such as phosphate buffered saline solution, distilled water, emulsion (such as oil / water emulsion), various types of wetting agents, sterile solutions, etc.). In some cases, the vaccine can be lyophilized and then reconstituted prior to administration. It is preferred to use a pharmaceutically suitable excipient or carrier compatible with mucosal (especially nasal, bronchial or pulmonary) administration for the purpose of colonization of the respiratory tract. See Remington's Pharmaceutical Sciences and USP / NF, which are standard texts in the art.
[0037] When formulated for mucosal administration, each dose of the vaccine can include a sufficient number of live Bordetella bacteria to cause colonization of the respiratory tract, for example, approximately (i.e., + / - 50%) 5×10 3 to 5×10 9 bacteria, depending on the body weight and age of the mammal receiving it. For administration to human subjects, the dose can include approximately 1×10 6 、5×10 6 、1×10 7 、5×10 7 、1×10 8 、5×10 8 、1×10 9 、5×10 9 、or 1×10 10 live Bordetella bacteria producing Fim3. The dose can be administered one or more times (2, 3, 4, 5, 6, 7, 8 times or more), at intervals of 1, 2, 3, 4, 5 or 6 days, or 1, 2, 3, 4, 5 or 6 weeks, or 1, 2, 3, 4, 5, 6 or 12 months. Generally, a sufficient amount of the vaccine is administered to cause colonization and a protective response. An additional amount is administered after the induced protective response wanes.
[0038] Method of eliciting an immune response to protect against whooping cough
[0039] The vaccines described herein can be administered to mammalian subjects (e.g., humans, human children or neonates, human adults, those at high risk of developing whooping cough complications, those with lung diseases, and those who are immunosuppressed or will become immunosuppressed) by any suitable method of depositing the bacteria within the vaccine in the respiratory tract. For example, the vaccine can be administered by inhalation or intranasal introduction (such as using an inhaler, syringe, insufflator, spray device, etc.). When administering a single dose of 1×10 4 to 1×10 7 (e.g., 1×10 4 、5×104 , 1×10 5 , 5×10 5 , 1×10 6 , 5×10 6 , or 1×10 7 + / - 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) of live bacteria is generally sufficient to induce protective immunity against the development of Bordetella infection (e.g., pertussis), and one or more (1, 2, 3, 4 or more) additional doses may be administered at intervals of 4 or more days (e.g., 4, 5, 6 or 7 days; or 1, 2, 3, 4, 5, 6, 7 or 8 weeks) until a sufficient protective immune response is produced. The development of a protective immune response may be assessed by methods known in the art, such as quantifying the titer of Bordetella-specific antibodies and measuring the response of Bordetella antigen-specific T cells (e.g., using an ELISPOT assay). In the event that the vaccine-induced protective immune response diminishes (e.g., 1, 2, 3, 4, 5, 10 years or more since the last vaccination), the vaccine may be administered to the subject again to enhance the anti-Bourdetella immune response.
[0040] Examples
[0041] Materials and Methods
[0042] Culture conditions
[0043] All B. pertussis strains were grown with agitation on Bordetella Gengou (BG) agar containing 10% (v / v) sheep blood in modified Stainer Scholte (SS) medium (Imaizumi et al., Infect Immun 1983; 41: 1138-43) as described or in completely synthetic Thijs medium (Thalen et al., J Biotechnol 1999; 75: 147-59). The medium was supplemented with appropriate antibiotics (100 ug / ml streptomycin, or 10 ug / ml gentamicin for strains carrying pFUS2 BctA1).
[0044] Bacterial strains
[0045] Bordetella pertussis BPSM and BPZE1, as well as Bordetella parapertussis used in this study, have been described previously (Mielcarek et al., PLoS Pathog [Public Library of Science Pathogens] 2006; 2: e65; Menozzi et al., Infect Immun [Infection and Immunity] 1994; 62: 769-78). Bordetella pertussis strains B0403, B1412, B1617 and B0005 (strain 134 Pillmer) were from the RIVM collection (Bilthoven, The Netherlands). For the purpose of counterselection, some clinical isolates were electroporated with the pFUS2 BctA1 suicide plasmid to obtain resistance to gentamicin as described by Antoine et al. (J Meth Mol Biol [Molecular Biology] 2005; 351: 799-809). As described below, the site of insertion of the pFUS2 BctA1 vector into the chromosomal DNA was verified by PCR, and the level of Fim2 and / or Fim3 exposed on the surface was checked by ELISA to check the gentamicin resistance derivatives after electroporation. The strain P134S was obtained by selecting the streptomycin derivative of Bordetella pertussis B0005. In addition to the streptomycin resistance mediated by the mutation in the rpsl gene, the strain P134S also carries a mutation in the fimC gene, resulting in a reduction in the production of pili. Escherichia coli SM10 (Simon et al., Bio / Technology [Biotechnology] 1983; 1: 784-91) was used to conjugate a variety of plasmid constructs into Bordetella pertussis.
[0046] Construction of Fim3-positive BPZE1 derivative BPZE1f3
[0047] To construct BPZE1f3, the 13 C segment located in the promoter region of the fim3 gene of BPZE1 (i.e., 75 bp upstream of the fim3ATG codon) was replaced with a 14 C segment to trigger transcription of fim3. The entire fim3 locus containing the promoter region was first deleted in the parent strain and then replaced with the fim3 locus with the 14 C segment. A 2265-bp PCR fragment containing the locus was amplified using the following oligonucleotides (SPfim3UP2: GAGCTCTTTACCGCGGCCGCCAGTTGTTCATCAATG and ASPfim3LO2: GGATCCATCATCGAGACCGACTGG) and cloned into the SacI and BamHI restriction sites of the pBluescript II SK+ plasmid (Addgene). A 904-bp fragment containing the entire locus was removed from the resulting plasmid by SphI restriction to obtain pSKfim3UPLO. The 1351-bp SacI-BamHI fragment of pSKfim3UPLO was inserted into the SacI and BamHI sites of pJQ200mp18rpsL (Antoine, J. Mol. Biol. (2005) 351, 799-809). The recombinant plasmid was then used for double homologous recombination in BPZE1 using conjugation as previously described (Mielcarek et al., PLoS Pathog [Public Library of Science Pathogens] 2006; 2: e65). The deletion of the entire fim3 locus in the transconjugants was checked by PCR using oligonucleotides SPfim3UP2 and ASPfim3LO2. The entire fim3 locus containing the 14 C segment in the promoter was reintroduced as follows. By A 911-bp synthetic gene containing the entire locus containing the 14 C segment was synthesized by gene synthesis (ThermoFisherSCIENTIFIC). The SphI site located at the end of the synthetic fragment was used to insert it into the SphI site of pSKfim3UPLO, resulting in pSKfim3+. The correct direction of insertion was checked by restriction. The 2256-bp SacI-BamHI fragment of this plasmid was transferred into the same restriction site of pJQ200mp18rpsL, resulting in pJQfim3+. This plasmid was used for double homologous recombination to obtain BPZE1f3. The recombinant strain was verified by PCR using oligonucleotides SPfim3UP2 and ASPfim3LO2.
[0048] Analysis of Fim2 and Fim3 production
[0049] First, the Bordetella pertussis strain was inactivated by heating at 56°C for 30 minutes. The heat-inactivated strain was then coated with an optical density (OD) of 0.075 at 600 nm in a 96-well plate (Nunc Maxi Sorp company), and incubated overnight at 37°C until the wells were dry. The wells were then blocked with 100 μl of PBS Tween 0.1% (PBST) containing 1% bovine serum albumin (BSA). Fim2 and Fim3 monoclonal antibodies (NIBSC company, 04 / 154 and 04 / 156, respectively) were added to a serial dilution of 1 / 50 to 1 / 36450 in PBST (v / v). After washing three times, the plate was incubated with 100 μl of horseradish peroxidase-labeled goat anti-mouse IgG (Southern Biotech, Inc. (Southern Biotech)) in PBST. After washing five times, the plate was incubated with 100 μl of HRP substrate TMB solution (Interchim) at room temperature for 30 min. The reaction was stopped by adding 50 μl of 1 M H3PO4. The OD was measured at 450 nm using a Biokinetic reader EL / 340 microplate.
[0050] DNA Sequencing
[0051] Chromosomal DNA was PCR amplified using Phusion high-fidelity DNA polymerase (Thermofisher) or KAPA HiFi DNA polymerase (Kapa Biosystems) according to the manufacturer's instructions. PCR fragments were purified with QiaQuick PCR purification kit (Qiagen) and sequenced with primers used for amplification. Primers ptxP Up and ptxPLow for PCR amplification of ptxP have been previously described (Mooi et al., Emerg Infect Dis [Emerging Infectious Diseases] 2009; 15: 1206-13). Primers prn AF and prn AR for PCR amplification of local prn have been previously described (Mooi et al., Emerg Infect Dis [Infection and Immunity] 1998; 66: 670-5). Primers fim2 Up 5′-AGCTAGGGGTAGACCACGGA-3′ and fim2 Low 5′-ATAACTCTTCTGGCGCCAAG-3′ were used for amplification and sequencing of fim2. Primers fim3 Up 5′-CATGACGGCACCCCTCAGTA-3′ and fim3 Low 5′-TTCACGTACGAGGCGAGATA-3′ were used for amplification and sequencing of fim3.
[0052] Mouse infection experiments
[0053] BALB / c mice were obtained from Charles River (l'Abresle, France) and maintained in the animal facility of the Institut Pasteur deLille under specific pathogen-free conditions. Six-week-old BALB / c mice were lightly sedated by intraperitoneal injection of an anesthetic mixture (ketamine+atropine+diazepam) and then administered intranasally (in) 20 μl of 10 6 PBS (Mielcarek et al., PLoS Pathog [Public Library of Science Pathogens] 2006; 2: e65) containing 1000 colony-forming units (CFU) of Bordetella pertussis BPZE1 or BPZE1f3. Three mice per group were sacrificed at selected time points after intranasal administration and their lungs were collected, homogenized in PBS and plated in serial dilutions onto BG-blood agar to count CFU after incubation at 37°C for three to four days.
[0054] Mouse protection experiment
[0055] Six-week-old BALB / c mice were inoculated intranasally with 10 5 Four weeks later, 10 CFU of Bordetella pertussis BPZE1 or BPZE1f3 were added to the culture medium in 20 μl of PBS. 6 Nude mice and vaccinated mice were challenged with 10 CFU of B. pertussis BPSM, the indicated clinical B. pertussis isolates, or B. parapertussis. Lung colonization was determined in 3 and 5 mice per group at 3 hours and 7 days, respectively.
[0056] Stability generated by Fim2 and Fim3
[0057] In 20 μl of PBS, 10 6CFU of BPZE1f3 were administered to sedated mice. After 14 days, the lungs were collected, homogenized and plated on BG agar. After 3-4 days, 94 individual colonies were inoculated into 96-well plates containing 100 μl PBS / well. Control wells containing BPZE1 served as negative controls, and control wells containing BPZE1f3 served as positive controls. The amount of bacteria present in each well was determined by OD measurement at 630 nm. After drying, the presence of Fim3 and Fim2 was assessed by whole cell ELISA as described above. After a blocking step with 100 μl PBST containing 1% BSA, the bacteria were incubated with anti-Fim3 monoclonal antibody 04 / 156 or anti-Fim2 monoclonal antibody 04 / 154 at a 1 / 1350 dilution in 100 μl PBST during one hour. After washing and incubation with 100 μl horseradish peroxidase-labeled goat anti-mouse IgG (Southern Biotech) in PBST, the presence of Fim3 or Fim2 was assessed with 100 μl HRP substrate TMB solution (Interchim). The reaction was stopped by adding 50 μl of 1 M H3PO4. OD was measured at 450 nm using a Biokinetic reader EL / 340 microplate.
[0058] result
[0059] Construction of BPZE1f3.
[0060] To construct a BPZE1 derivative that produces Fim3, the fim3 gene was first deleted from BPZE1. Using BPZE1 chromosomal DNA as a template, the upstream and downstream flanking regions of fim3 were amplified by PCR and spliced together in the non-replicating vector pJQ200mp 18rpsL (Antoine, J. Mol. Biol. [Journal of Molecular Biology] (2005) 351, 799-809). The fim3 gene of BPZE1 was then deleted by conjugating it to E. coli SM10 containing a recombinant plasmid and performing an allelic exchange. The resulting strain BPZE1Δfim3 was used to reintegrate the fim3 gene and a functional promoter into the original fim3 locus. The 13-C segment of the original promoter was replaced by the 14-C segment, thereby allowing fim3 expression, and was inserted into pSKfim3UPLO together with the fim3 open reading frame. The resulting plasmid pJQFim3+ was conjugated into BPZE1Δfim3 by conjugation with E. coli SM10:pJQFim3+, thereby generating BPZE1f3.
[0061] The production of Fim2 and Fim3 in BPZE1f3 was analyzed by whole-cell ELISA using Fim2-specific and Fim3-specific monoclonal antibodies, respectively. Figure 1 As shown in A, both BPZE1 and BPZE1f3 produced equal amounts of Fim2. In contrast, Fim3 was produced only by BPZE1f3, and only background absorbance was detected using a Fim3-specific antibody on whole BPZE1 extracts ( Figure 1 B) Both strains grew equally well in Stainer Scholte medium and in completely synthetic Thijs medium ( Figure 2 ), indicating that the production of Fim3 does not affect the growth characteristics of BPZE1f3.
[0062] Colonization of mice by BPZE1f3.
[0063] To evaluate the potential role of Fim3 produced by BPZE1f3 in the colonization of the mouse respiratory tract, 10 6 Adult mice were infected with 10 CFU of BPZE1 or BPZE1f3, and 3 mice in each group were sacrificed on days 3, 7, 14, 21, and 28 after infection to quantify the bacterial load in their lungs. Figure 3 As shown, the ability of both strains to colonize the mouse lungs was equivalent at all time points analyzed, indicating that Fim3 production neither enhances nor impedes the ability of BPZE1 to colonize the murine airways.
[0064] BPZE1-mediated and BPZE1f3-mediated protection against clinical isolates of Bordetella pertussis.
[0065] To examine the relative protective effects of BPZE1 and BPZE1f3 against clinical isolates that differ in the production of Fim2 and Fim3, we used a suboptimal immunization schedule in which 10 5 Mice were immunized intranasally with 10 CFU of the vaccine strain and one month later with 10 6 This protocol was used because it is best suited to detect potential differences between vaccine batches, as the standard vaccination protocol (using 10 6 Two months later, 10 6 CFU challenge strain infection) is usually completely cleared by day 7 after challenge.
[0066] The efficacy of these two vaccine strains was tested against four different clinical isolates from the Bordetella pertussis culture collection of RIVM (Bilthoven, The Netherlands). These five strains have the following characteristics in terms of Fim2 and Fim3 production: 1617F1 (Fim2+Fim3-), 403pF1 (Fim2+Fim3-), P134 (Fim2-Fim3-), 1412pF1 (Fim2-Fim3+) and 403pF3 (Fim2+Fim3+). The genome key features of these strains are presented in Table 1 below. After vaccination and stimulating infection, the bacterial load of the stimulating strain in the lung was measured 3 hours and on the 7th day after infection.
[0067] Table I. Key genomic features of B. pertussis strains.
[0068]
[0069] 1 Promoter type of pertussis toxin gene.
[0070] 2 Genotype of pilus gene
[0071] 3 Pertactin gene alleles
[0072] 4 Pertussis toxin subunit S1 allele
[0073] BPZE1 and BPZE1f3 protected equally well against 1617pF1, 403pF1, P134, and 403pF3, reducing the bacterial load by 4 to 5 log in each case at day 7 post-infection compared with the bacterial load in unvaccinated mice. Figure 4 There were no statistically significant differences between mice vaccinated with BPZE1 and mice vaccinated with BPZE1f3. However, when mice were challenged with 1412pF1 (a strain that produces only Fim3 and not Fim2), BPZE1f3 appeared to be significantly better protected than BPZE1 ( Figure 4D). BPZE1 vaccination resulted in a 4 log difference in bacterial load compared to unvaccinated mice, while BPZE1f3 improved this protection to a 5 log difference. When CFU were measured 3 hours after challenge infection, no statistically significant reduction in bacterial load was observed between vaccinated and unvaccinated mice, indicating that, as expected, all mice received the same challenge dose. These results indicate that BPZE1f3 has improved efficacy relative to BPZE1 against strains producing only Fim3, while protection against strains producing Fim3 and Fim2 or Fim2 and not Fim3, or against strains that do not produce pili, is not improved.
[0074] BPZE1-mediated and BPZE1f3-mediated protection against Bordetella parapertussis.
[0075] BPZE1f3 was also tested for its efficacy against B. parapertussis. 6 CFU vaccine strains, and then 10 6 CFU of B. parapertussis challenge. This regimen has been shown previously to result in robust protection, although complete clearance was not achieved by day 7 post-challenge infection (Mielcarek et al., PLoS Pathog [Public Library of Science Pathogens] 2006; 2: e65). At day 7 post-challenge with B. parapertussis, mice vaccinated with both BPZE1 and BPZE1f3 showed a significant reduction (between 4 and 5 logs) in bacterial load in the lungs compared with unvaccinated mice ( Figure 5 No statistical differences were seen between mice vaccinated with BPZE1 and BPZE1f3, suggesting that Fim3 production does not provide an advantage nor is detrimental to protection against B. parapertussis infection.
[0076] BPZE1f3 generates the stability of Fim3.
[0077] Since the only genetic difference between BPZE1 and BPZE1f3 is the amount of C in the C strand of the fim3 promoter (13 C in BPZE1 and 14 C in BPZE1f3), and since the C strand is susceptible to phase shifts in B. pertussis (Willems et al., EMBO J [Journal of the European Molecular Biology Association] 1990; 9: 2803-9), the stability of BPZE1f3 in producing both Fim3 and Fim2 was assessed after passage of the vaccine strain in mice. 6Mice were infected with 100 CFU of BPZE1f3, and bacteria present in the lungs 14 days after infection were collected and plated on BG agar. After growth, 94 individual colonies were inoculated into 96-well plates. The remaining colonies were collected and applied to mice for a second passage, and then a third passage was performed 2 weeks later. At each passage, 94 individual colonies were inoculated into a 96-well plate containing 100 μl of PBS / well. Control wells containing BPZE1 served as negative controls, and control wells containing BPZE1f3 served as positive controls. The amount of bacteria present in each well was determined by measuring OD at 630 nm. After drying, the presence of Fim3 and Fim2 was evaluated by whole cell ELISA. After the first passage, 94 of the 94 clones were found to produce both Fim3 and Fim2. After the second passage, 97.9% of the colonies produced Fim2, and 96.8% of the colonies produced Fim3; and after the third passage, the number of colonies producing Fim3 and Fim2 was 87.23% and 97.9%, respectively ( Figure 6 ), which indicated that fim3 expression was relatively stable and only lost 12.77% after three in vivo passages.
[0078] The present invention also provides the following items:
[0079] 1. A vaccine comprising a pharmaceutically acceptable carrier and a live attenuated Bordetella strain engineered to stably produce Fim3, wherein the live attenuated Bordetella strain retains the ability to colonize the lungs of a mammalian subject and to induce a protective immune response against Bordetella infection.
[0080] 2. The vaccine according to claim 1, wherein the live attenuated Bordetella strain stably produces Fim2.
[0081] 3. The vaccine according to item 1, wherein the live attenuated Bordetella strain has been determined to lack at least one virulence factor selected from the group consisting of: functional pertussis toxin (PTX), functional dermonecrotic toxin (DNT) and functional tracheal cytotoxin (TCT).
[0082] 4. The vaccine according to item 1, wherein the live attenuated Bordetella strain has been determined to lack at least two virulence factors selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0083] 5. The vaccine according to claim 1, wherein the live attenuated Bordetella strain has been determined to lack PTX, functional DNT and functional TCT.
[0084] 6. The vaccine according to item 2, wherein the live attenuated Bordetella strain has been determined to lack at least one virulence factor selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0085] 7. The vaccine according to item 2, wherein the live attenuated Bordetella strain has been determined to lack at least two virulence factors selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0086] 8. The vaccine according to item 2, wherein the live attenuated Bordetella strain has been determined to lack functional PTX, functional DNT and functional TCT.
[0087] 9. The vaccine according to claim 1, wherein the vaccine is provided in a single dosage form, the single dosage form comprising at least 1 x 10 6 colony forming units (CFU) of the strain.
[0088] 10. The Bordetella strain was designated BPZE1f3.
[0089] 11. A method for protecting a mammalian subject from pertussis, the method comprising the steps of administering to the mammalian subject a vaccine comprising a pharmaceutically acceptable carrier and a live attenuated Bordetella strain engineered to stably produce Fim3, wherein the live attenuated Bordetella strain retains the ability to colonize the lungs of the mammalian subject and to induce a protective immune response against Bordetella infection.
[0090] 12. The method according to item 11, wherein the attenuated live Bordetella strain stably produces Fim2.
[0091] 13. The method according to item 11, wherein the attenuated live Bordetella strain has been determined to lack at least one virulence factor selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0092] 14. The method according to item 11, wherein the attenuated live Bordetella strain has been determined to lack at least two virulence factors selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0093] 15. The method according to item 11, wherein the attenuated live Bordetella strain has been determined to lack functional PTX, functional DNT and functional TCT.
[0094] 16. The method according to item 12, wherein the live attenuated Bordetella strain has been determined to lack at least one virulence factor selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0095] 17. The method according to item 12, wherein the live attenuated Bordetella strain has been determined to lack at least two virulence factors selected from the group consisting of: functional PTX, functional DNT and functional TCT.
[0096] 18. The method according to item 12, wherein the live attenuated Bordetella strain has been determined to lack functional PTX, functional DNT and functional TCT.
[0097] 19. The method according to item 11, wherein the strain is BPZE1f3.
[0098] Other embodiments
[0099] It should be understood that although the invention has been described in conjunction with its specific embodiments, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.
Claims
1. A Bordetella strain engineered to stably express Fim3 by adding a single cytosine:guanine base pair in a segment of 13 cytosines in the promoter region of the fim3 gene.
2. A live attenuated Bordetella strain that stably produces Fim2 and Fim3 and lacks at least one virulence factor selected from the group consisting of: functional pertussis toxin (PTX), functional dermonecrotic toxin (DNT) and functional tracheal cytotoxin (TCT), wherein the live attenuated Bordetella strain retains the ability to colonize the lungs of mammalian subjects and induce a protective immune response against Bordetella infection.
3. The strain according to claim 2, wherein the live attenuated Bordetella strain lacks at least two of the following: functional PTX, functional DNT and functional TCT.
4. The strain according to claim 2, wherein the live attenuated Bordetella strain lacks functional PTX, functional DNT and functional TCT.
5. A method for preparing a Bordetella strain that stably produces Fim2 and Fim3, the method comprising the following steps: Providing a Bordetella strain that stably produces Fim2 but not Fim3; and The Bordetella strain that stably produces Fim2 but not Fim3 is genetically engineered to stably express Fim3.
6. The method of claim 5, wherein the step of genetically engineering the Bordetella strain comprises modifying the promoter region of the fim3 gene to increase BvgA-mediated activation of transcription of the fim3 gene.
7. The method of claim 5, wherein the Bordetella strain that stably produces Fim2 but not Fim3 lacks at least one of functional PTX, functional DNT, and functional TCT.
8. The method of claim 5, wherein the Bordetella strain that stably produces Fim2 but not Fim3 lacks at least two of functional PTX, functional DNT, and functional TCT.
9. The method of claim 5, wherein the Bordetella strain that stably produces Fim2 but not Fim3 lacks functional PTX, functional DNT, and functional TCT.
10. A method of preparing a vaccine comprising a live attenuated Bordetella strain that retains the ability to colonize the lungs of a mammalian subject and to induce a protective immune response against Bordetella infection, the method comprising the steps of: Providing a live attenuated Bordetella strain that stably produces Fim2 but not Fim3; genetically engineering the live attenuated Bordetella strain that stably produces Fim2 but not Fim3 to stably express Fim3; The genetically engineered strain is mixed with a pharmaceutically acceptable carrier.
11. The method of claim 10, wherein the step of genetically engineering the live attenuated Bordetella strain comprises modifying the promoter region of the fim3 gene to increase BvgA-mediated activation of transcription of the fim3 gene.
12. The method of claim 10, wherein the live attenuated Bordetella strain that stably produces Fim2 but not Fim3 lacks at least one of functional PTX, functional DNT, and functional TCT.
13. The method of claim 10, wherein the live attenuated Bordetella strain that stably produces Fim2 but not Fim3 lacks at least two of functional PTX, functional DNT, and functional TCT.
14. The method of claim 10, wherein the live attenuated Bordetella strain that stably produces Fim2 but not Fim3 lacks functional PTX, functional DNT, and functional TCT.
15. Use of a live attenuated Bordetella strain for the preparation of a medicament for preventing Bordetella infection, wherein the Bordetella strain stably produces Fim2 and Fim3 and lacks functional PTX, functional DNT and functional TCT.
